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ABSTRACT
Introduction: The present study aimed to
inform an economic evaluation of dabrafenib
and trametinib combination as first-line
treatment of metastatic melanoma in a
Canadian setting. A network meta-analysis was
conducted to estimate hazard ratios (HRs) for
progression-free survival (PFS)and overall
survival (OS) of dabrafenib plus trametinib
versus other first-line treatments of BRAF
mutation-positive metastatic melanoma
including dabrafenib, trametinib, vemurafenib,
ipilimumab, and dacarbazine (DTIC).
Methods: HRs for PFS and OS were from
randomized controlled trials identified from
systematic literature reviews. HRs for PFS and
OS (adjusted for crossover as appropriate) were
analyzed using multivariate and univariate
Bayesian network meta-analysis.
Results: In multivariate network-meta analyses
(HRs for PFS and OS estimated simultaneously
to account for the correlation of treatment
effects on PFS and OS), HRs (95% credible
interval) for PFS and OS favored dabrafenib
plus trametinib [PFS: 0.23 (0.18–0.29) versus
DTIC, 0.32 (0.24–0.42) versus ipilimumab plus
DTIC, 0.52 (0.32–0.83) versus trametinib, 0.57
(0.48–0.69) versus vemurafenib, and 0.59
(0.50–0.71) versus dabrafenib]; OS [0.41
(0.29–0.56) versus DTIC, 0.52 (0.38–0.71)
versus ipilimumab plus DTIC, 0.68 (0.47–0.95)
versus trametinib, 0.69 (0.57–0.84) versus
vemurafenib, and 0.72 (0.60–0.85) versus
dabrafenib]. The beneficial effects on OS of
dabrafenib plus trametinib versus ipilimumab
plus DTIC and versus trametinib were
attenuated when HRs were estimated using
univariate network meta-analysis (HRs for PFS
and OS estimated separately).
Conclusion: This analysis demonstrates
improved PFS and OS with
dabrafenib ? trametinib versus dabrafenib,
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INTRODUCTION
The treatment of metastatic melanoma has
been transformed in recent years by the
introduction of immune checkpoints
inhibitors and therapies targeted on the MAP
kinase (MAPK) pathway. Immune checkpoint
inhibitors block proteins on cytotoxic T-cells or
cancer cells which inhibit T cell signaling, such
as the cytotoxic lymphocyte-associated protein
4 (CTLA-4) or the programmed death-1 (PD-1)
protein, thus reactivating an immune system
response against tumor cells. Ipilimumab, an
anti-CTLA-4 antibody, was the first immune
checkpoint inhibitor to be approved in
melanoma. In controlled trials, ipilimumab
has demonstrated consistent activity against
melanoma in pretreated and
chemotherapy-naı¨ve patients [1–3]. More
recently, two novel anti-PD-1 immune
checkpoint inhibitors, pembrolizumab and
nivolumab, have been approved based on
randomized controlled trials demonstrating
improved outcomes versus ipilimumab alone
[4–6].
Dysregulation of BRAF signaling in theMAPK
pathway is a key driver of metastatic melanoma
[7]. Two inhibitors of the BRAF protein,
vemurafenib and dabrafenib, have been
approved for treatment of patients with BRAF
V600 mutation-positive unresectable stage IIIC
or stage IV (advanced or metastatic) melanoma.
These approvals were based on the results of the
BRIM-3 (ClinicalTrials.gov identifier:
NCT01006980) and BREAK-3 (ClinicalTrials.gov
identifier: NCT01227889) randomized
controlled trials, respectively, which
demonstrated improved outcomes versus
dacarbazine (DTIC) in front-line treatment of
BRAF V600 mutation-positive unresectable or
metastatic melanoma [8–14]. Trametinib is a
highly potent and selective small-molecule
inhibitor of the MEK kinase that is downstream
of and activated by BRAF in the MAPK pathway.
Trametinib has been shown to be more effective
than chemotherapy in treatment-naı¨ve or
previously treated patients with BRAF V600
mutation-positive unresectable or metastatic
melanoma [15]. These results, as well as
improved understanding of the mechanisms of
resistance to targeted therapies, have led to the
exploration of combination approaches to
targeted therapy. The efficacy and safety of
dabrafenib in combination with trametinib has




trials, as well as the phase 2 BRF113220
(ClinicalTrials.gov identifier: NCT01072175)
trial [16–21]. Results of these trials have
demonstrated that dabrafenib plus trametinib
improves progression-free survival (PFS) and
overall survival (OS) compared with dabrafenib
monotherapy or vemurafenib monotherapy
treatment-naı¨ve patients with BRAF V600
mutation-positive unresectable or metastatic
melanoma.
Economic evaluations of novel treatments
such as dabrafenib plus trametinib require
estimates of the relative treatment effects
versus other available therapies on PFS and OS.
The objective of this study was to conduct a
network meta-analysis of HRs for PFS and OS of
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dabrafenib plus trametinib versus other
first-line treatments of BRAF mutation-positive
advanced or metastatic melanoma for use in an
economic evaluation of dabrafenib plus
trametinib in this indication for submission to
Canadian reimbursement authorities.
METHODS
This studywas a networkmeta-analysis of HRs for
PFS and OS reported in randomized controlled
trials of first-line treatments for patients with
BRAF mutation-positive advanced or metastatic
melanoma. Comparatorswere limited to first-line
treatments for patients with metastatic
melanoma that were approved by Health
Canada as of February 2015 and included
dabrafenib plus trametinib, dabrafenib,
vemurafenib, trametinib, ipilimumab, and
DTIC. Nivolumab, pembrolizumab, and
cobimetinib plus vemurafenib were not included
in the analysis as these treatments were not yet
approved of that date.
Trials included in the analysis were identified
from two systematic literature reviews. Details
regarding the reviews have been published
previously [22, 23]. Both reviews followed the
Preferred Reporting Items for Systematic Reviews
and Meta-analysis (PRISMA) guidelines [24]. The
first review was undertaken to evaluate efficacy,
safety, and tolerability of dabrafenib and
trametinib monotherapy versus other first-line
treatments for unresectable advanced or
metastatic melanoma [22]. The second review
was undertaken to evaluate the efficacy and
safety of the dabrafenib plus trametinib therapy
compared to other first-line or second-line
treatments for patients with unresectable or
metastatic melanoma [23]. For both reviews,
Embase, MEDLINE (including MEDLINE
In-Process and other non-indexed citations),
Cochrane Central Trials Register, and key
conferences (i.e., American Society of Clinical
Oncology, European Society for Medical
Oncology/European Cancer Organization,
International Congress of the Society for
Melanoma Research) were searched.
Additionally, data reported in public assessment
reports from the EuropeanMedicines Agency and
Food and Drug Administration websites were
searched, as were Health Technology Assessment
(HTA) guidance documents published in English
from selected HTA authorities (e.g., National
Institute for Health and Care Excellence). The
first review included randomized and
non-randomized studies of dabrafenib,
trametinib, DTIC, ipilimumab, vemurafenib,
fotemustine, and temozolomide published
through October 2012. The second review
included randomized studies of dabrafenib plus
trametinib, dabrafenib, trametinib,
vemurafenib-cobimetinib combination,
vemurafenib, ipilimumab, nivolumab, and
pembrolizumab published through October
2015. For both reviews, screening and extraction
was conducted by two independent reviewers.
The first review identified 123 studies which
met all inclusion criteria, of which 24 were
randomized controlled trials in treatment-naı¨ve
patients [22]. The second review identified 12
randomized controlled trials of one ormoreof the
treatment of interest in patients with
unresectable or metastatic melanoma [23].
Combiningthe resultsof these tworeviews, and
focusing on trials of previously untreated patients
receiving any one of the comparators approved in
Canada at the timeof the analysis, andwhichwere
required to estimate HRs for PFS and OS for the
comparators versus dabrafenib plus trametinib,
yielded seven studies, including the COMBI-d and
BRF113220 (dabrafenib–trametinib versus
dabrafenib), COMBI-v (dabrafenib–trametinib
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versus dabrafenib), BREAK-3 (dabrafenib versus
DTIC), BRIM-3(vemurafenib versus DTIC),
METRIC (ClinicalTrials.gov identifier:
NCT01245062, trametinib versus chemotherapy),
and CA184-024 (ClinicalTrials.gov identifier:
NCT00324155, ipilimumab plus DTIC vs DTIC).
HRs for PFS and OS were based on analyses of the
most recent data cuts available from each trial at
the time the evaluation was completed
[9, 13, 15, 16, 18, 20, 25]. HRs for PFS and OS
from the METRIC trial were based on analyses of
the first-line subgroup. HRs for OS from the
BRIM-3, BREAK-3, METRIC, and BRF113220 trials
were based on Rank Preserving Structural Failure
Time (RPSFT) analyses to adjust for crossover from
control to active therapy [10, 14, 26, 27]. HRs for
PFS andOS for ipilimumabwerebasedon results of
the CA184-024 trial [25]. Although this trial
included both BRAF mutation-positive and BRAF
wild-type patients, it was the only study available
at the time of the analysis that reported both PFS
and OS for ipilimumab as first-line treatment of
metastatic melanoma. Also, although the
approved dosage for ipilimumab is 3 mg/kg q3w
as monotherapy, this trial compared ipilimumab
10 mg/kg plusDTIC versusDTIC. In the economic
evaluation which this analysis informed, results
for ipilimumab 10 mg/kg plus DTIC were used to
estimate outcomes for patients receiving the
approved dosage.
HRs were estimated by Bayesian network
meta-analysis using WinBUGS 1.4.3 (MRC
Biostatistics Unit, Cambridge, UK) with input
data taking the form of the log transformed HRs
from each trial and the corresponding standard
errors [28]. For each comparison, the log HRs for
PFS and OS were estimated alternatively using
multivariate network meta-analysis (in which
treatment effects on PFS and OS were estimated
simultaneously) and using traditional or
univariate network meta-analysis (in which
the analyses of PFS and OS were conducted
separately). A multivariate network
meta-analysis uses the correlation of the HRs
for PFS and OS in the network to inform
parameter estimation [29]. The use of this
approach is reasonable given the
well-established correlation between treatment
effects on PFS and OS in metastatic melanoma
[30].
Given the small number of trials with which
to estimate random effects (in the analysis
assuming no class effect for BRAF inhibitors,
there was only one comparison for which there
was more than one trial to estimate the random
effects), a fixed effects model was employed.
Model parameters were estimated using the
WinBUGS software package (version 1.43)
(Medical Research Council (MRC) Biostatistics
Unit (BSU), Cambridge, UK). WinBUGS code
used in the analysis are provided in the
supplementary material.
Two sets of analyses were performed. In one,
it was assumed that the effects of dabrafenib
and vemurafenib on PFS and OS may be
different (‘‘no class-effect’’), and separate HRs
were estimated for dabrafenib and vemurafenib.
In the other analysis, it was assumed that the
effects of dabrafenib and vemurafenib on PFS
and OS are the same (‘‘class effect’’). In this
analysis, HRs for other comparators versus BRAF
inhibitor monotherapy were calculated. This
analysis permitted the combining of data on
PFS and OS from the COMBI-d, COMBI-v, and
BRF113220 trials in order to potentially
improve the precision of the comparisons.
Both analyses were conducted alternatively
including and excluding the phase 2
BRF113220 trial. Multivariate network
meta-analyses (in which the HRs for PFS and
OS were estimated simultaneously to account
for the correlation of these outcomes), were
conducted both including and excluding
trametinib and ipilimumab plus DTIC from
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the network, in order to account for the
possibility that the correlation between
treatment effects on OS and PFS differ by drug
class.
The heterogeneity of effect sizes reported for
all direct comparisons with multiple sources of
direct evidence was evaluated using Cochrane’s
Q and the I2 statistics. Consistency of direct and
indirect comparisons within closed loops
defined by the evidence network was
confirmed by plotting the confidence intervals
(CIs) of the difference in log HRs between direct
and indirect comparisons.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Evidence network diagrams for PFS and OS for
the analysis assuming no class-effect for BRAF
inhibitors and the analysis assuming class-effect
for BRAF inhibitor are shown in Fig. 1a, b,
respectively. In the latter analysis, HRs for PFS
and OS for the comparison of dabrafenib plus
trametinib versus BRAF inhibitor monotherapy
from COMB-v, COMBI-d and BRF113220 are
pooled, as are the HRs for BRAF inhibitor
monotherapy versus DTIC from BREAK-3 and
BRIM-3.
Study design and patient characteristics are
reported in Table 1. COMBI-v was the largest
trial; BRF113220 was the smallest. Mean age
ranged from 49 years (BRF113220, dabrafenib
plus trametinib 1 mg) to 58 years (BRF113220,
dabrafenib plus trametinib 2 mg). The percent
male ranged from 49% (METRIC, DTIC) to 63%
(BRF113220, dabrafenib plus trametinib 2 mg).
The percent with Eastern Cooperative Oncology
Group performance status[0 ranged from 25%
(COMBI-d, dabrafenib plus trametinib) to 37%
(BRF113220, dabrafenib). The percent with
stage M1C at diagnosis ranged from 55%
(CA184-024, DTIC) to 70% (BRF113220,
dabrafenib plus trametinib 2 mg). The percent
with elevated lactate dehydrogenase ranged
from 30% (BREAK-3, DTIC) to 58% (BRIM-3,
DTIC).
HRs used in the network meta-analyses are
shown in Table 2. The HRs for PFS for the
research arm versus the control arm were
statistically significant for all trials. The HR for
OS for the research arm versus the control arm
was statistically significant for COMBI-v,
COMBI-d, BRIM-3, and CA184-024. Note that
the HRs for OS for BREAK-3, BRIM-3, METRIC,
and BRF113220 are based on RPSFT analyses
that adjust for crossover from control to active
therapy. The 95% CIs for these HRs are
therefore relatively wide compared to those in
other trials.
Results of the network meta-analysis on HRs
for PFS and OS for the analysis assuming no
class-effect for BRAF inhibitors are shown in
Table 3 and in Fig. 2. All HRs (95% CrI) for PFS
significantly favored dabrafenib plus
trametinib: 0.23 (0.18–0.29) versus DTIC, 0.32
(0.24–0.42) versus ipilimumab plus DTIC, 0.52
(0.32–0.83) versus trametinib, 0.57 (0.48–0.69)
versus vemurafenib, and 0.59 (0.50–0.71) versus
dabrafenib. All HRs (95% CrI) for OS also
significantly favored dabrafenib plus
trametinib: 0.41 (0.29–0.56) versus DTIC, 0.52
(0.38–0.71) versus ipilimumab plus DTIC, 0.68
(0.47–0.95) versus trametinib, 0.69 (0.57–0.84)
versus vemurafenib, and 0.72 (0.60–0.85) versus
dabrafenib. Results were similarly in favor of
dabrafenib plus trametinib when the Phase II
BRF113220 trial was excluded from the
network. Excluding ipilimumab plus DTIC and
trametinib from the network had little impact
on the HRs for the other therapies. When HRs
Oncol Ther (2016) 4:239–256 243






























Fig. 1 Evidence network for network meta-analyses of hazard ratios for progression-free survival and overall survival.
a Analysis assuming no class-effect for BRAF inhibitors, b assuming class-effect for BRAF inhibitors. DTIC dacarbazine
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for PFS and OS were estimated separately using
univariate network meta-analysis (i.e., without
accounting for the correlation of treatment
effects on PFS and OS), the beneficial effects
on OS of dabrafenib plus trametinib versus
ipilimumab plus DTIC and dabrafenib plus
trametinib versus trametinib were reduced
compared with estimates from the multivariate
analysis in which the HRs for PFS and OS were
estimated simultaneously (compared with
trametinib, HR = 0.68 for multivariate analysis
versus 0.98 for univariate analysis; compared
with ipilimumab plus DTIC, HR = 0.52 for
multivariate analysis versus 0.60 for univariate
analysis).
Results of the network meta-analysis on HRs
for PFS and OS for the analysis assuming a
class-effect for BRAF inhibitors are shown in
Fig. 3. These results were generally similar to
those for the analysis in which separate HRs
were estimated for dabrafenib and vemurafenib
monotherapy. When all trials and treatments
Table 2 HRs for PFS and OS used in network meta-analysis






RPSFT HR 95% CI
PFS
COMBI-v Dabrafenib ? trametinib Vemurafenib 17-Apr-14 352 352 n/a 0.56 0.46 0.69
COMBI-d Dabrafenib ? trametinib Dabrafenib 12-Jan-15 211 212 n/a 0.67 0.53 0.84
BRF113220 Dabrafenib ? trametinib Dabrafenib 15-Jan-15 54 54 n/a 0.41 0.27 0.64
BREAK-3 Dabrafenib DTIC 25-Jun-12 187 63 n/a 0.37 0.23 0.57
BRIM-3a Vemurafenib DTIC 12-Feb-12 337 338 n/a 0.38 0.32 0.46
METRICb Trametinib DTIC 26 Oct 11 114 62 n/a 0.44 0.28 0.69
CA184-24 Ipilimumab ? DTIC DTIC n/r 247 251 n/a 0.76 0.63 0.93
OS
COMBI-v Dabrafenib ? trametinib Vemurafenib 17-Apr-14 352 352 No 0.69 0.53 0.89
COMBI-d Dabrafenib ? trametinib Dabrafenib 12-Jan-15 211 212 No 0.71 0.55 0.92
BRF113220 Dabrafenib ? trametinib Dabrafenib 29-Mar-13 54 54 Yes 0.47 0.13 1.66
BREAK-3 Dabrafenib DTIC 18-Dec-12 187 63 Yes 0.55 0.21 1.43
BRIM-3 Vemurafenib DTIC 12-Feb-12 337 338 Yes 0.64 0.47 0.88
METRICa Trametinib DTIC 16-May-13 114 62 Yes 0.44 0.20 1.00
CA184-024 Ipilimumab ? DTIC DTIC n/r 247 251 No 0.72 0.59 0.87
HR hazard ratio, PFS progression-free survival, OS overall survival, DTIC dacarbazine, RPSFT rank preserving structural
failure time
a The reported conﬁdence interval for the RPSFT adjusted HR for OS for BRIM-3 (HR = 0.64, 95% CI 0.53–0.78)
implied a lower p value than that from the intent-to-treat analysis (HR = 0.76, 95% CI 0.63–0.93). Since the RPSFT
method does not increase statistical power, the reported conﬁdence interval was assumed to be erroneous. The conﬁdence
interval used in the analysis was obtained by solving for the standard error on the log(HR) which yielded the same p value as
the corresponding intent-to-treat analysis
b First-line subgroup of primary efﬁcacy population
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were included, the HRs for PFS and OS for
dabrafenib plus trametinib were significantly
less than 1.0 for all comparisons. The HRs and
95% CrI for dabrafenib plus trametinib versus
trametinib, ipilimumab plus DTIC, and DTIC
were similar to those obtained in the analysis in
which no class-effect was assumed.
For all comparisons of OS based on multiple
sources of direct evidence, the I2 statistic was
estimated to be 0%, indicating no identifiable
heterogeneity. For PFS, significantheterogeneity
of treatment effects was observed only for the
PFS HR for the comparison of dabrafenib plus
trametinib versus dabrafenib based on COMBI-d
Fig. 2 Results of network meta-analyses of HRs for progression-free survival and overall survival for dabrafenib plus
trametinib versus other treatments. HR hazard ratio, DTIC dacarbazine
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and BRF113220 (Q = 3.873, p = 0.049,
I2 = 74.2%). When assuming a class effect,
COMBI-V is included in the comparison,
heterogeneity remains elevated, but drops
below the threshold for significance
(Q = 4.338, p = 0.114, I2 = 53.9%). No
heterogeneity was identified in the comparison
of BRAF monotherapies and DTIC based on
BREAK-3 and BRIM-3 (Q = 0.011, p = 0.915,
I2 = 0.0%). There was no evidence of
inconsistency of direct and indirect estimates
of treatment effects within the closed loop
formed by the BREAK-3, BRIM-3, COMBI-v, and
COMBI-d studies, as theCIs for the differences of
log HRs between direct and indirect effects
spanned zero for both PFS and OS.
Fig. 3 Results of network meta-analyses of HRs for progression-free survival and overall survival for dabrafenib plus
trametinib versus other treatments assuming class effect for BRAF inhibitors. HR hazard ratio, DTIC dacarbazine
Oncol Ther (2016) 4:239–256 249
DISCUSSION
This study was a network meta-analysis of HRs
for PFS and OS of dabrafenib plus trametinib
versus other first-line treatments of BRAF
mutation-positive metastatic melanoma that
was conducted to inform an economic
evaluation of dabrafenib plus trametinib as
first-line treatment of metastatic melanoma in
Canada. Results of this analysis suggest that
dabrafenib plus trametinib yields improved PFS
and OS compared to other first-line treatment
for BRAF mutation-positive metastatic
melanoma. The results for
dabrafenib-trametinib were more favorable
compared with trametinib and ipilimumab
plus DTIC when HRs for PFS and OS were
estimated using multivariate network
meta-analysis to account for the correlation of
treatment effects on PFS and OS than when they
were estimated separately using traditional
univariate network meta-analysis. Results were
generally similar when it was assumed there was
a class effect on PFS and OS for BRAF inhibitor
monotherapy compared with analyses in which
no such assumption was made. Results also were
similar when the phase 2 BRF113220 trial was
included or excluded.
A targeted search identified several network
meta-analyses of treatments for metastatic
melanoma [22, 31–34]. Two of these articles
focused on comparisons of chemotherapies and
interferon [32, 33]. One study focused on
comparisons of ipilimumab versus
immunotherapies, chemotherapies, and
biochemotherapies, but did not consider BRAF
or MEK inhibitors [34]. Srivastava and
colleagues conducted a systematic review and
indirect treatment comparison of dabrafenib
and trametinib as monotherapy versus other
treatments in previously untreated metastatic
melanoma patients; this study did not include
BRAF-MEK combination therapy, however [22].
Only one study was identified that included
dabrafenib plus trametinib [31]. This study by
Mai and colleagues compared BRAF-MEK
inhibition with BRAF inhibitor monotherapy,
MEK inhibitor monotherapy, BRAF inhibitor
plus chemotherapy, and MEK inhibitor plus
chemotherapy [31]. The study did not consider
ipilimumab. The authors reported that
combined BRAF–MEK inhibition significantly
prolonged PFS compared with BRAF inhibition
alone (HR = 0.58, 95% CI 0.51–0.67, p\0.0001)
and MEK inhibition alone (HR = 0.29, 95% CI
0.22–0.37, p\0.0001). Similar results were
obtained for OS for BRAF–MEK inhibition
versus BRAF inhibition, (HR = 0.67, 95% CI
0.56–0.81, p\0.0001) and for BRAF–MEK
inhibition versus MEK inhibition (HR = 0.48,
95% CI 0.36–0.65, p\0.0001). These results are
qualitatively similar to those reported herein.
Limitations of this study should be noted.
Perhaps most importantly, this analysis did not
consider new immunotherapies such as
nivolumab and pembrolizumab, or the
combination of vemurafenib plus the MEK
inhibitor, cobimetinib, as these therapies were
not approved in Canada at the time this
analysis was conducted and therefore were not
required in the economic evaluation for which
this network meta-analysis was performed.
Future network meta-analyses of therapies for
metastatic melanoma should include these
novel treatments if feasible. It should be
noted, however, that the robustness of any
such analyses will depend on the availability of
efficacy data on both PFS and OS in patients
with BRAF mutations positive disease.
Differences in patients, study design, and
duration of follow-up may have affected
treatment effects thus violating the similarity
assumption and confounding the comparisons.
For example, the COMBI-d and CA184-024
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trials were double-blind, whereas the other trials
in the network were open label. The CA184-024
trial included both BRAF mutation-positive and
wild-type patients. These factors may modify
treatment effects and bias the comparisons.
Given the small number of studies it was not
possible to assess the impact of these differences
on results.
This study used HRs as the measure of
treatment effect. Use of HRs requires an
assumption of proportional hazards which
may not hold across all studies. Ouwens et al.
[35] have described an approach for conducting
a network meta-analysis of parametric survival
distributions that may address the limitations of
conducting the analysis based on HRs.
However, this approach requires additional
assumptions regarding the similarity of
underlying parametric survival distributions
across trials that may not hold. Nevertheless,
this is a potentially important area for future
research.
The approved dosage for ipilimumab in
North America and Europe is 3 mg/kg once
every three weeks. However, the systematic
literature reviews did not identify any
controlled trials of ipilimumab monotherapy
versus DTIC at this dosage. Accordingly, the
HRs for PFS and OS for ipilimumab 10 mg/kg
plus DTIC versus DTIC from the CA184-024
trial were used in the evidence network. The use
of the results of this analysis to estimate the
relative efficacy of ipilimumab monotherapy
3 mg/kg versus other comparators requires the
assumptions (1) that there is no difference in
treatment effect on PFS and OS for the 10 and
3 mg/kg doses of ipilimumab and (2) that the
addition of DTIC to ipilimumab has no impact
on treatment effects on PFS or OS. Data on the
impact of the addition of DTIC to ipilimumab
on outcomes are limited and inconclusive. In
the MDX010-08 trial, an open label phase 2
study of ipilimumab 3 mg/kg plus DTIC versus
ipilimumab 3 mg/kg in 76 previously treated
patients with metastatic melanoma [36], the
addition of DTIC to ipilimumab was associated
with nominally improved response, PFS, and
OS. These results were not conclusive, however,
given the small size of the trial. Median PFS was
99 and 85 days in the ipilimumab plus DTIC
and ipilimumab groups, respectively. Median
OS was 14.3 versus 11.4 months for the
ipilimumab plus DTIC and ipilimumab groups,
respectively.
Regarding the assumption that the efficacy
of ipilimumab 10 mg/kg is equivalent to 3 mg/
kg, the CA184-004 trial compared ipilimumab 3
versus 10 mg/kg in a mixed population of 101
melanoma patients with and without prior
treatment. There was no evidence of improved
PFS or OS with 10 versus 3 mg/kg in this trial
[37, 38]. The CA184-022 trial compared 0.3, 3,
and 10 mg/kg in 214 previously treated patients
with melanoma [39, 40]. This study
demonstrated a statistically significant
dose–response relationship on best overall
response rates. Median OS and 1- and 2-year
survival rates were nominally improved with
ipilimumab 10 mg/kg compared with 3 and
0.3 mg/kg. These results are suggestive that
adding DTIC to ipilimumab may provide some
benefit and that 10 mg/kg may improve
outcomes versus 3 mg/kg. Accordingly, the use
of the CA184-024 trial to estimate the relative
effectiveness of ipilimumab 3 mg/kg versus
DTIC may bias estimates of the relative
effectiveness in favor of ipilimumab and versus
BRAF and MEK inhibitors.
Trials of BRAF and MEK inhibitors focused
on patients with BRAF mutations, whereas the
CA184-024 trial focused on a mix of patients
with BRAF mutations and wild-type (WT)
disease. Known BRAF mutation status was not
required for inclusion in the CA184-024 trial
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and data on PFS and OS for subgroups of
patients defined on BRAF mutation status have
not been reported. Evidence suggests that
BRAF-mutant melanoma is biologically distinct
from BRAF WT disease [41–44]. Also, numerous
studies have shown that BRAF-mutant
melanoma is associated with more aggressive
disease and worse patient outcomes [41–47].
Because data on treatment effects for
ipilimumab versus DTIC by BRAF mutation
status are unavailable, it was not possible to
assess potential effect modification from this
factor.
To the best of our knowledge, this is the first
study to use both univariate and multivariate
network meta-analysis to estimate HRs for PFS
and OS. Multivariate network meta-analysis of
HRs for PFS and OS accounts for the
well-established correlation of treatment
effects on PFS and OS. In the COMBI-d,
COMBI-v, BREAK-3, and BRIM-3 trials,
treatment effects on PFS were greater than
treatment effects on OS. In the METRIC trial,
the estimated treatment effect of trametinib on
OS was equal to that on PFS (HR = 0.44 for
both). In the CA184-024 trial, the estimated
treatment effect of ipilimumab plus DTIC on OS
was greater than that on PFS (HR = 0.76 for PFS
and HR = 0.72 for OS). As a consequence, the
multivariate network meta-analysis attenuated
the estimated treatment effects on OS for
trametinib and ipilimumab plus DTIC. For
example, the HR for OS for trametinib versus
DTIC observed in METRIC was 0.44 (95% CI
0.20–1.00), whereas that obtained from the
multivariate network meta-analysis was 0.60
(95% CI 0.41–0.83). Similarly, the HR for OS
for ipilimumab plus DTIC versus DTIC observed
in CA184-024 was 0.72 (95% CI 0.59–0.87),
whereas that obtained from the multivariate
network meta-analysis was 0.78 (95% CI
0.67–0.90). The results of these analyses may
be biased if there are unique attributes of
trametinib and ipilimumab that would result
in differential relative effects on OS versus PFS
compared with the other therapies. For
trametinib, we know of no reason to believe
that this would be the case; rather, it is more
likely a consequence of the small number of
subjects in the first-line subgroup of the
METRIC trial and the imprecision in the RPSFT
method for adjustment for crossover. For
ipilimumab, however, it is possible that the
immune-related effects may be delayed relative
to the cytotoxic effects of BRAF and MEK
inhibitors, which would explain a relatively
large effect on OS versus that on PFS. The
analysis based on the multivariate network
meta-analysis may have biased the results in
favor of the combination and against
ipilimumab plus DTIC therefore should be
interpreted cautiously.
CONCLUSION
In conclusion, this network meta-analysis
demonstrates improved PFS and OS with
dabrafenib plus trametinib versus dabrafenib,
trametinib, vemurafenib, ipilimumab, and
DTIC as first-line therapy for patients with
BRAF mutation-positive metastatic melanoma.
Future research should be conducted which
includes other novel treatments, if feasible,
and based on network meta-analysis of
survival distributions rather than HRs to
account for non-proportionality of hazards.
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